We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Michael A. Charles
Michael A. Charles
Products
PRODUCTS
L.M. Manufacturing Ltd.
Michael A. Charles
Price:
$117.00
View
KBI Biopharma, Inc.
Michael A. Charles
and
Nicholas L. Hunt
Price:
$117.00
View
Tolmar, Inc.
Michael A. Charles
and
Zachary L. Stamm
Price:
$117.00
View
OSO BioPharmaceuticals Manufacturing, LLC
Michael A. Charles
Price:
$117.00
View
K.C. Pharmaceuticals, Inc.
Michael A. Charles
and
Diane R. Weidley
Price:
$117.00
View
Aurobindo Pharma Ltd., Unit V
Michael A. Charles
Price:
$117.00
View
Jiangsu Grand Xinyi Pharmaceutical Co., Ltd.
Michael A. Charles
Price:
$117.00
View
Wuxi Fortune Pharmaceutical Co., Ltd.
Michael A. Charles
Price:
$117.00
View
Dexcel Pharma, Ltd.
Michael A. Charles
and
Ivis L. Negron Torres
Price:
$117.00
View
Dexcel Pharma Technologies Ltd.
Michael A. Charles
and
Ivis L. Negron Torres
Price:
$117.00
View
View All Products by Michael A. Charles
Upcoming Events
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
27
Jul
Applying the Lessons of the Pandemic to Your Upcoming Trial
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
10
Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek
Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher
FDA Approves Beyond Air’s LungFit PH for Newborn Pulmonary Hypertension
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More